The Zangmeister Cancer Center in Columbus, Ohio has joined the American Oncology Network, LLC and the Sarah Cannon Research Institute as a strategic research site, according to a press release by AON.
The Zangmeister Cancer Center (Zangmeister) in Columbus, Ohio has joined the American Oncology Network, LLC (AON) and the Sarah Cannon Research Institute as a strategic research site, according to a press release by AON.
Zangmeister is being joined in the partnership with Hematology/Oncology Clinic in Baton Rouge, Louisiana, and Messino Cancer Centers in Asheville, North Carolina. As part of the partnership, clinical trials will be offered as part of Zangmeister’s services.
The current oncology staff at Zangmeister include Tarek Chidiac, MD, Patrick Elwood, MD, Mark Knapp, MD, Jeanna Knoble, MD, Sameh Mikhail, MD, Timothy Moore, MD, Taral Patel, MD Jorge Rios, MD, Mark Segal, MD, FACP, Kothai Sundaram, MD, Emily Whitman, MD, Jeffrey Zangmeister, MD and Gynecologic Oncologist Luis Vaccarello, MD, FACOG.
“The physicians at Zangmeister Cancer Center are truly dedicated to improving the lives and the health of their patients,” said AON CEO Todd Schonherz in a press release. “Their partnership with Sarah Cannon Research Institute enables access to a broader range of innovative research studies within the community, matching patients with potentially life-saving treatments.”
AON’s network of cancer care centers currently expands 16 states. Practices in the network offer laboratory, pathology, and oral pharmacy services so patients can receive all their care at a single location. Research has found that having a compressive center close to a patient’s home helps to improve well-being. Currently, AON, which was founded in 2018, incudes 92 physicians and 62 nurse practitioners and physician assistants. Due to its size, the network is able to aggregate value and attain economies of scale to reduce per-capital cancer care cost.
AON has incorporated practices in Washington DC, Washington State, Nevada, Arizona, Arkansas, Georgia, Iowa, Kentucky, Virginia, Ohio, Indiana, Missouri, Louisiana, North Carolina, South Carolina, and Michigan.2
The Sarah Cannon Research Institute has currently conducted over 500 first-in-human trials since 1993 and helped to pioneer one of the first community-based oncology drug development programs in the United States. The center has enrolled thousands of people into clinical trials annually throughout its network of partners.
“By expanding our collaboration with AON, we will further advance our mission to bring the latest therapies through clinical trials into the Columbus, Ohio community,” said Howard A. Burris, III, MD president of clinical operations and chief medical officer at Sarah Cannon Research Institute in a press release. “We look forward to working together with the experts at Zangmeister Cancer Center to provide even greater access to cutting-edge therapies that patients vitally need, close to home.”